Navigation Links
ACell's CEO to Present at Rodman & Renshaw's 2009 Annual Global Investment Conference

COLUMBIA, Md., Sept. 2 /PRNewswire/ -- ACell, Inc. is announcing its participation at Rodman & Renshaw's 2009 Annual Global Investment Conference.

The conference will be held September 9, 2009 through September 11, 2009 at the New York Palace Hotel in New York City. James DeFrancesco, Chief Executive Officer and President, is scheduled to make an investor presentation on September 11th beginning at 9:10 AM (EDT) in the Hubbard Room. The presentation is expected to take approximately 25 minutes. Investors and strategic partners interested in ACell's proprietary technology are encouraged to contact the company for private one on one discussion while attending the conference.

Mr. DeFrancesco's presentation will provide an update on ACell's regenerative medicine technology and share clinical results of recently completed cases. ACell introduced its wound care devices utilizing a major marketing partner last January. Now, with the recent release of several new extracellular matrix (ECM) surgical devices, ACell is targeting the US plastic surgery, hernia and trauma markets. Several orthopedic products are scheduled for release next year. The company has recently received significant media coverage for the involvement of its MatriStem((R)) MicroMatrix(TM) in re-growing severed fingertips.

ACell Inc.

ACell is a private company with multiple US and international patents for its proprietary UBM (Urinary Bladder Matrix) ECM technology. ACell's advanced bio-scaffold devices consist of an intact epithelial basement membrane, naturally derived bioactive molecules and multiple collagen types known to assist the body in the regeneration of new tissues. Commercially branded as MatriStem((R)), UBM can be used in a broad range of regenerative medicine applications. ACell currently has five FDA 510(k) clearances addressing wound care and various surgical indications.

SOURCE ACell, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Transcept Pharmaceuticals to Present at the BioCentury Thomson Reuters Newsmakers in the Biotech Industry Conference on September 16, 2009
2. BioMarin to Present at the Baird Healthcare Conference
3. Poniard Pharmaceuticals To Present at Three Upcoming Investor Conferences in September
4. NeurogesX to Present at Upcoming Fall Conferences
5. Repligen to Present at the Rodman & Renshaw 11th Annual Healthcare Conference Wednesday, September 9th, 2:25 p.m. EDT
6. Optimer Pharmaceuticals Announces Presentations of Additional Phase 3 Fidaxomicin and Prulifloxacin Data at Upcoming ICAAC Annual Meeting
7. Jiangbo Pharmaceuticals to Present at Rodman & Renshaw Annual Global Investment Conference
8. Express Scripts to Present at Investor Conferences
9. ERT to Present at Bairds 2009 Health Care Conference on September 9, 2009
10. PharmAthene to Present at the Rodman and Renshaw Annual Global Investment Conference September 10, 2009
11. PAREXEL International to Present at Robert Baird 2009 Healthcare Conference
Post Your Comments:
(Date:11/25/2015)... BRUSSELS , November 25, 2015 ... la première fois les différences entre les souches ... de celles des êtres humains . Ces ... comprendre et envisager la prise en charge efficace de ... ent diagnostiqués chez les chats .    --> ...
(Date:11/25/2015)... and HOLLISTON, Mass. , ... Inc. (Nasdaq: HART ), a biotechnology company developing ... CEO Jim McGorry will present at the ... 1, 2015 at 2:30 p.m. PT. The presentation will ... for 30 days. Management will also be available at ...
(Date:11/25/2015)... 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS; TSX: ... prospects remain fundamentally strong and highlights the following ... received DSMB recommendation to continue the ZoptEC Phase ... the final interim efficacy and safety data ... men with heavily pretreated castration- and Taxane-resistant prostate ...
(Date:11/25/2015)... SAN DIEGO , Nov. 25, 2015 ... that management will participate in a fireside chat discussion ... New York . The discussion is ... Time. .  A replay will ... Contact:  Media Contact:McDavid Stilwell  , Julie NormartVP, Corporate ...
Breaking Biology Technology:
(Date:11/10/2015)... YORK , Nov. 10, 2015 ... to behavioral biometrics that helps to identify and ... fraud. Signature is considered as the secure and ... the identification of a particular individual because each ... more accurate results especially when dynamic signature of ...
(Date:11/2/2015)... 2, 2015  SRI International has been awarded a ... development services to the National Cancer Institute (NCI) PREVENT ... scientific expertise, modern testing and support facilities, and analytical ... and toxicology studies to evaluate potential cancer prevention drugs. ... PREVENT Cancer Drug Development Program is an NCI-supported pipeline ...
(Date:10/29/2015)... 2015  Rubicon Genomics, Inc., today announced an ... its DNA library preparation products, including the ThruPLEX ... Plasma-seq kit. ThruPLEX Plasma-seq has been optimized for ... libraries for liquid biopsies--the analysis of cell-free circulating ... in cancer and other conditions. Eurofins Scientific is ...
Breaking Biology News(10 mins):